Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus - 24/01/23
Highlights |
• | Question: H1-antihistamines (AHs) may exert protective effects against cancer. Does any protective effect of AHs on hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection? |
• | Findings: The adjusted hazard ratios for AH users with diabetes (compared with AH nonusers with diabetes) were significantly associated with decreased HCC incidence, regardless of age, sex, comorbidities, medications, diabetes medications, and diabetes severity. |
• | Meaning: AH use may reduce HCC in patients with T2DM in a dose-dependent manner. |
Abstract |
Purpose |
H1-antihistamines (AHs) may exert protective effects against cancer. We investigated the association of AH use with hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Methods |
The data of patients with T2DM enrolled from Taiwan's National Health Insurance Research Database were examined for the period of January 1, 2008, to December 31, 2018. We used the Kaplan–Meier method and Cox proportional hazards regression to evaluate the AH use–HCC risk association.
Results |
After 1:1 propensity score matching was performed, the two cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 0.70; 95% CI, 0.60 to 0.84), respectively. The dose–response relationship between AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 28–35, 36–49, 50–77, and >77 cumulative defined daily doses of AH, respectively).
Conclusion |
AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.
Le texte complet de cet article est disponible en PDF.Keywords : H1-Antihistamines, Hepatocellular Carcinoma, incidence rate ratio, Type 2 Diabetes Mellitus, dose-dependent
Abbreviations : aHR, CI, NSAID, aDCSI, AH, cDDD, IQR, SD, N, SMD, HR, IR, IRR, HCC, T2DM, HBV, HCV, IGT, PSM, NHI, NHIRD, IGF-1, TNF-α, IL-6
Plan
Vol 49 - N° 1
Article 101393- janvier 2023 Retour au numéro
Article précédent
- Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: A prospective cohort study
- Julie Pires Da Silva, Matthieu Wargny, Jérémy Raffin, Mikaël Croyal, Thibaut Duparc, Guillaume Combes, Annelise Genoux, Bertrand Perret, Bruno Vellas, Sophie Guyonnet, Claire Thalamas, Dominique Langin, Cédric Moro, Nathalie Viguerie, Yves Rolland, Philipe de Souto Barreto, Bertrand Cariou, Laurent O. Martinez, the MAPT/DSA Group
- Physical activity and diabetes mortality in people with type 2 diabetes: a prospective cohort study of 0.5 million US people
- Maria Reyes Beltran-Valls, Verónica Cabanas-Sánchez, Kabir P. Sadarangani, Fernando Rodríguez-Artalejo, Diego Moliner-Urdiales, David Martínez-Gómez
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?